Literature DB >> 29275448

The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population.

Patricia D Jones1,2, Carlos Diaz3, Danlu Wang4, Joselin Gonzalez-Diaz5, Paul Martin5,6, Erin Kobetz6,7,8.   

Abstract

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) incidence is increasing at differential rates depending on race. We aimed to identify associations between race and survival after HCC diagnosis in a diverse American population.
METHODS: Using the cancer registry from Sylvester Comprehensive Cancer Center, University of Miami and Jackson Memorial Hospitals, we performed retrospective analysis of 999 patients diagnosed with HCC between 9/24/2004 and 12/19/2014. We identified clinical characteristics by reviewing available electronic medical records. The association between race and survival was analyzed using Cox proportional hazards regression.
RESULTS: Median survival in days was 425 in Blacks, 904.5 in non-Hispanic Whites, 652 in Hispanics, 570 in Asians, and 928 in others, p < 0.01. Blacks and Asians presented at more advanced stages with larger tumors. Although Whites had increased severity of liver disease at diagnosis compared to other races, they had 36% reduced rate of death compared to Blacks, [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.51-0.8, p < 0.01]. After adjusting for significant covariates, Whites had 22% (HR 0.78, 95% CI 0.61-0.99, p 0.04) reduced risk of death, compared to Blacks. Transplant significantly reduced rate of death; however, only 13.3% of Blacks had liver transplant, compared to 40.1% of Whites, p < 0.01.
CONCLUSIONS: In this diverse sample of patients, survival among Blacks is the shortest after HCC diagnosis. Survival differences reflect a more advanced tumor stage at presentation rather than severity of underlying liver disease precluding treatment. Improving survival in minority populations, in whom HCC incidence is rapidly increasing, requires identification and modification of factors contributing to late-stage presentation.

Entities:  

Keywords:  Disparities; Hepatocellular carcinoma; Race

Mesh:

Year:  2017        PMID: 29275448     DOI: 10.1007/s10620-017-4869-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  Socioeconomic status and hepatocellular carcinoma in the United States.

Authors:  Fatma M Shebl; David E Capo-Ramos; Barry I Graubard; Katherine A McGlynn; Sean F Altekruse
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-05       Impact factor: 4.254

2.  Race not rural residency is predictive of surgical treatment for hepatocellular carcinoma: Analysis of the Texas Cancer Registry.

Authors:  Zeinab M Alawadi; Uma R Phatak; Lillian S Kao; Tien C Ko; Curtis J Wray
Journal:  J Surg Oncol       Date:  2015-12-22       Impact factor: 3.454

3.  Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States.

Authors:  Li Xu; Yuhree Kim; Gaya Spolverato; Faiz Gani; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

4.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

5.  Orthotopic liver transplantation in a multiethnic population: role of spatial accessibility.

Authors:  N Kemmer; A Alsina; G W Neff
Journal:  Transplant Proc       Date:  2011-12       Impact factor: 1.066

6.  Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

Authors:  Jian-Min Yuan; Sugantha Govindarajan; Kazuko Arakawa; Mimi C Yu
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

7.  Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.

Authors:  Sean F Altekruse; S Jane Henley; James E Cucinelli; Katherine A McGlynn
Journal:  Am J Gastroenterol       Date:  2014-02-11       Impact factor: 10.864

8.  Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States.

Authors:  Avo Artinyan; Brian Mailey; Nicelio Sanchez-Luege; Joshua Khalili; Can-Lan Sun; Smita Bhatia; Lawrence D Wagman; Nicholas Nissen; Steven D Colquhoun; Joseph Kim
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Influence of socioeconomic status on survival of hepatocellular carcinoma in the Ontario population; a population-based study, 1990-2009.

Authors:  Nathaniel Jembere; Michael A Campitelli; Morris Sherman; Jordan J Feld; Wendy Lou; Stuart Peacock; Eric Yoshida; Murray D Krahn; Craig Earle; Hla-Hla Thein
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

View more
  14 in total

1.  At diagnosis of hepatocellular carcinoma, African Americans with hepatitis C have better liver function than other patients.

Authors:  Adam C Winters; Julie C Sung; Brooke Wyatt; Deeva Berera; Thomas D Schiano; Myron E Schwartz; Ponni V Perumalswami; Andrea D Branch
Journal:  Clin Liver Dis (Hoboken)       Date:  2018-11-06

2.  Hepatocellular Carcinoma in HIV-Infected Patients: Clinical Presentation and Outcomes in a Racially Diverse Urban Population.

Authors:  Angelica D'Aiello; Numa Rahman; N Patrik Brodin; Manish Dave; Sakshi Jasra; Andreas Kaubisch; Rafi Kabarriti; Jennifer Chuy
Journal:  J Gastrointest Cancer       Date:  2022-05-09

3.  Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

Authors:  Colby S Shemesh; Phyllis Chan; Hui Shao; Derek-Zhen Xu; Daniel Combs; Shweta Vadhavkar; René Bruno; Benjamin Wu
Journal:  Liver Cancer       Date:  2021-06-10       Impact factor: 11.740

4.  Mitoquinol mesylate (MITOQ) attenuates diethyl nitrosamine-induced hepatocellular carcinoma through modulation of mitochondrial antioxidant defense systems.

Authors:  Rahmat Adetutu Adisa; Lateef Adegboyega Sulaimon; Ebele Geraldine Okeke; Olubukola Christianah Ariyo; Fatimah B Abdulkareem
Journal:  Toxicol Res       Date:  2021-11-08

5.  Racial and Sex Disparities in Hepatocellular Carcinoma in the USA.

Authors:  Faith Ajayi; Jenny Jan; Amit G Singal; Nicole E Rich
Journal:  Curr Hepatol Rep       Date:  2020-11-12

6.  Acceptability and Feasibility of Home-Based Hepatitis B Screening Among Haitian Immigrants.

Authors:  Patricia D Jones; Kristin Gmunder; Saradjine Batrony; Paul Martin; Erin Kobetz; Olveen Carrasquillo
Journal:  J Immigr Minor Health       Date:  2021-03-09

7.  Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C.

Authors:  Ponni V Perumalswami; Brooke Wyatt; Chip A Bowman; Krupa Patel; Anna Mageras; Sara C Lewis; Andrea D Branch
Journal:  Cancer Med       Date:  2022-03-09       Impact factor: 4.711

8.  Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study.

Authors:  Zhensheng Wang; Xiangjun Gu; Aaron P Thrift
Journal:  PLoS One       Date:  2019-04-03       Impact factor: 3.240

9.  Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis.

Authors:  Nicole E Rich; Christian Carr; Adam C Yopp; Jorge A Marrero; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2020-12-30       Impact factor: 11.382

10.  Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype.

Authors:  Tali Shaltiel; Serena Zheng; Cleo Siderides; Elizabeth M Gleeson; Jacquelyn Carr; Eric R Pletcher; Noah A Cohen; Benjamin J Golas; Deepa R Magge; Daniel M Labow; Andrea D Branch; Umut Sarpel
Journal:  Cancer       Date:  2021-02-25       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.